Michael Kowarik | cso
LimmaTech Biologics AG

Michael Kowarik, cso, LimmaTech Biologics AG

As Chief Scientific Officer, Michael is responsible for LimmaTech’s scientific development, focusing on pipeline development and operational R&D performance. Michael has a PhD in Biochemistry from the Swiss Federal Institute of Technology, Zurich (ETH Zurich) and developed a broad experience in the biotech industry. After university, he joined GlycoVaxyn AG to develop the company’s bioconjugation vaccine platform through its early stages. As VP Research and IP, he was responsible for the innovation of platform science and the collaboration with GSK that culminated in GlycoVaxyn’s acquisition by GlaxoSmithKline plc in February 2015. After that, Michael joined LimmaTech as a co-founder, and soon took the role of VP Business Strategy and IP to drive LimmaTech’s proprietary business, marking his journey into therapeutics. With the successful spin-out of the therapeutics assets into the newly formed company GlycoEra AG in January 2021, he moved back to his true scientific passion, vaccines.


Day 2 - Wednesday 30th October @ 14:30

A Novel Vaccine Against Neisseria Gonorrhoeae

Day 2 - Wednesday 30th October @ 15:30

The Role of Vaccines & mAbs in Neonatal Sepsis Prevention

last published: 10/Jun/24 12:45 GMT

back to speakers